%0 Journal Article
%T Discovery of RXFP2 genetic association in resistant hypertensive men and RXFP2 antagonists for the treatment of resistant hypertension.
%A Zhang SS
%A Larrabee L
%A Chang AH
%A Desai S
%A Sloan L
%A Wang X
%A Wu Y
%A Parvez N
%A Amaratunga K
%A Hartman AC
%A Whitnall A
%A Mason J
%A Barton NP
%A Chu AY
%A Davitte JM
%A Csakai AJ
%A Tibbetts CV
%A Tolbert AE
%A O'Keefe H
%A Polanco J
%A Foley J
%A Kmett C
%A Kehler J
%A Kozejova G
%A Wang F
%A Mayer AP
%A Koenig P
%A Foletti D
%A Pitts SJ
%A Schnackenberg CG
%J Sci Rep
%V 14
%N 1
%D 2024 06 8
%M 38851835
%F 4.996
%R 10.1038/s41598-024-62804-7
%X Hypertension remains a leading cause of cardiovascular and kidney diseases. Failure to control blood pressure with ≥ 3 medications or control requiring ≥ 4 medications is classified as resistant hypertension (rHTN) and new therapies are needed to reduce the resulting increased risk of morbidity and mortality. Here, we report genetic evidence that relaxin family peptide receptor 2 (RXFP2) is associated with rHTN in men, but not in women. This study shows that adrenal gland gene expression of RXFP2 is increased in men with hypertension and the RXFP2 natural ligand, INSL3, increases adrenal steroidogenesis and corticosteroid secretion in human adrenal cells. To address the hypothesis that RXFP2 activation is an important mechanism in rHTN, we discovered and characterized small molecule and monoclonal antibody (mAb) blockers of RXFP2. The novel chemical entities and mAbs show potent, selective inhibition of RXFP2 and reduce aldosterone and cortisol synthesis and release. The RXFP2 mAbs have suitable rat pharmacokinetic profiles to evaluate the role of RXFP2 in the development and maintenance of rHTN. Overall, we identified RXFP2 activity as a potential new mechanism in rHTN and discovered RXFP2 antagonists for the future interrogation of RXFP2 in cardiovascular and renal diseases.